



THE CANCER DRUG DEVELOPMENT FORUM

FACILITATE. DEBATE. ACTIVATE. INNOVATE.

Promoting Multi-Stakeholder Collaboration to Advance Oncology Therapeutics.



WHAT IS THE CDDF

The Cancer Drug Development Forum (CDDF) is a non-profit organisation registered in Belgium that provides a neutral platform to stimulate interaction between stakeholders involved in cancer drug development.

OUR MISSION

The CDDF's mission is to facilitate collaboration between stakeholders, to increase efficiency in cancer drug development, and accelerate the delivery of effective oncology treatment to patients.

• HOW WE ADVANCE OUR MISSION

- The CDDF provides a non-competitive, non-commercial platform for multi-stakeholder discussions and collaboration
- The CDDF brings together all actors in the oncology community such as academia, the healthcare industry, regulatory authorities, health technology assessment (HTA) bodies, policymakers, and patient advocacy groups
- The CDDF stimulates advancement and innovation in the field through scientific debate and open discussion





INITIATIVES

For many years, the Cancer Drug Development Forum (CDDF) has stimulated discussions to accelerate effective drug development in oncology treatment, as well as shorten the time to market, and to patient access.

The CDDF offers workshops, conferences and webinars, which bring together stakeholders involved in cancer drug development to a productive dialogue in a neutral, non-competitive space.

The association drives multiple activities and initiatives in **close contact with regulators** from both the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA), additional national regulatory agencies, **HTAs**, **academic researchers** from around the globe, **healthcare companies**, and **patient advocates**.





FACILITATE. DEBATE. ACTIVATE. INNOVATE.

The Cancer Drug Development Forum (CDDF) **Annual Conference** is a unique meeting which facilitates open, meaningful dialogue. This multi-stakeholder, interactive, three-day gathering, offers plenary lectures with moderated discussions, including case studies and networking opportunities.

The agile, responsive nature of the CDDF platform allows **programs to be quickly initiated or adapted to reflect current and pressing issues**. The CDDF has also clearly proved to be a **visionary force within the cancer drug development field** addressing topics such as immuno-oncology, real-world data in cancer drug development, histology independent drug development, MRT & ctDNA in oncology, diversity in oncology clinical trials, and the combination of immunotherapy and radiotherapy.

The CDDF continues to **pioneer progress in cancer drug treatments** through workshops and webinars exploring topics affecting the future of cancer care, such as real-world evidence, decentralised care and trials, drug and biomarker combinations, clinical research in Central and Eastern Europe, and innovation in rare cancers.

The association also publishes executive summaries, white papers, and meeting reports from workshops discussions, conference presentations, and lecture briefings in order to increase knowledge of the challenges and opportunities in cancer drug development.



CDDF MEETINGS BRING
TOGETHER REGULATORS,
HTAS, THE HEALTHCARE
INDUSTRY, ACADEMICS, AND
PATIENT ADVOCATES TO
COLLABORATE

COLLABORATIVE NETWORK
OF MULTI-STAKEHOLDERS
INVOLVED IN ONCOLOGY
DRUG DEVELOPMENT

CDDF LEADERSHIP



The CDDF is governed by a rotating board of directors dedicated to the development of cancer drugs, representing a range of perspectives within the drug development process.

These distinguished academics are experienced pre-clinical and clinical investigators, medical oncologists, statistician, regulatory scientists, and pharmacists who have experience working within regulatory agencies, the pharmaceutical industry, and patient advocacy.

The chairperson and directors are elected for a period of three years.

CDDF BOARD OF DIRECTORS



Ruth Plummer Chairperson



Stefan SymeonidesVice-Chairperson



Glasmacher
Treasurer



VerweijManaging Director



Catarina Edfjaëll



Mark



Eva Skolvlund



Rosa Giuliani



Christian Schneider



Fergus Sweeney

CDDF OFFICE

CDDF staff members oversee the day to day running of the organisation. The head office is located in Brussels, Belgium.



Coppens Director of Operations



Giorgia Campagnano **Event Manager**



Shannon Adeux **Event Coordinator**



Davidova Community & Communication Coordinator



CDDF ACTIVITIES 2025



Click the buttons to view detailed information

MULTI-STAKEHOLDER DISCUSSIONS

Cancer Drug Development Forum (CDDF)

ANNUAL CONFERENCE 2025

Challenges, Advances, and Open Questions in Global Cancer Drug Development and Clinical Trials

3-5 February 2025

Noordwijk aan Zee, NL

MULTI-STAKEHOLDER WORKSHOP

New Modalities in
Cancer Drug
Development

31 March - 1 April 2025
Brussels, BE (hybrid)

<u>Programme</u>

Executive Summary

<u>Programme</u>

Executive Summery



MULTI-STAKEHOLDER WORKSHOP

Accelerating drug development to deliver better patient care

17 - 18 November 2025 Brussels, BE (hybrid)



<u>Programme</u>

Registration



AAADV-ASCO-CDDF Workshop Global Oncology Drug Development

15-16 May 2025, Washington D.C. (US)

(Available soon)

CDDF ACTIVITIES 2025





CDDF WEBINAR SERIES

EU HTA Regulation (2025)

Concluded

Concluded

Concluded



Al and Big Data Al in Drug Development:

Using AI in assessing cancer treatment response on imagine: Project

Data Sphere



Bayesian Framework:

Bayesian Approaches in Oncology Drug Development: Introduction and Motivations

SAVE THE DATE

18/09/2025



Al and Big Data Al in drug development:

Transformation of future clinical trials using Al-enhanced imaging biomarkers

SAVE THE DATE

04/12/2025



Long term outcomes of in utero exposure to cytotoxic therapy: Is involving pregnant patients an absolute no-go in cancer drug development?

SAVE THE DATE

ACT EU Series: Overview of ACT EU (2025)

15/12/2025



MEETING OUTCOMES 2024

Click the buttons to view meeting outputs

CDDF Annual Conference 2024: Changing paradigms to accelerate oncology drug development (5 - 7 February 2024, NL)

Executive summary

White paper

Recordings/slides

Multi-Stakeholder Workshop in Central and Eastern Europe: New Approaches for the Next Level of Development (15 – 16 April 2024, PL)

Executive summary

White paper (available soon)

Recordings/slides

ESMO Congress 2024: ESMO-CDDF Educational Session: Regulatory Challenges in Clinical Cancer Drug Development(16 September 2024, SP)

<u>Executive</u> <u>summary</u> White paper (available soon)

CDDF&EORTC Multi-Stakeholder joint Workshop: Innovation and Access in Rare Cancers
(23-24 September 2024, NL)

<u>Executive</u> <u>summary</u>

White paper (available soon)

Recordings/slides

*Recent meeting recordings and slides are accessible exclusively to the CDDF Industry Members, the CDDF Full Association Member, Patient Advocates, HTAs, and regulators (FDA, EMA, HTAs and national agencies) for educational purposes

MEETING OUTCOMES 2024

Click the buttons to view meeting outputs

CDDF Live Webinar: COVID-19 and

Cancer: Time for a Reset to repair the

damage done

(15 January 2024)

<u>Key takeaways</u>

Recordings/slides

CDDF Live Webinar:

Clinical Research in Central and Eastern Europe: Realising the opportunities

(12 February 2024)

Key takeaways

Recordings/slides

CDDF Live Webinar:

Cancer Medicines Forum:
Advancing Cancer Treatment
Optimization Across Europe
(25 June 2024)

<u>Key takeaways</u>

Recordings/slides

CDDF Live Webinar:

Bayesian Approaches in Drug Development(11 July 2024)

Key takeaways

Recordings/slides

CDDF Live Webinar series: Al and Big Data in Cancer Drug Development

An introduction to the use of AI in cancer drug development and regulatory considerations

<u>Key takeaways</u>

Recordings/slides

(29 October 2024)

CDDF Live Webinar:

EU Clinical Trial Regulations

(12 November 2024)

<u>Key takeaways</u>

Recordings/slides



COLLABORATION AND OPEN DIALOGUE AMONG ALL STAKEHOLDERS ARE KEY TO IMPROVING OUTCOMES FOR CANCER PATIENTS







in The Cancer Drug Development Forum (CDDF)

Cancer Drug Development Forum asbl
Clos Chapelle-aux-Champs 30, 1200 Woluwe Saint Lambert, Belgium

